Related Experiment Videos
Refractory atypical absence seizures in rat: a two hit model
Irina Serbanescu1, Miguel A Cortez, Colin McKerlie
1Division of Neurology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ont., Canada M5G 1X8.
Epilepsy Research
|November 3, 2004
Summary
Researchers developed a new rat model for medically refractory seizures in children. This model, using methylazoxymethanol acetate (MAM) and AY-9944, mimics brain abnormalities and seizures, aiding in epilepsy research.
Area of Science:
- Neuroscience
- Developmental Neuroscience
- Epileptology
Background:
- Medically refractory seizures in children often stem from congenital brain malformations.
- Existing animal models do not adequately replicate these complex seizure disorders.
Purpose of the Study:
- To establish a novel animal model for studying medically refractory seizures associated with brain dysgenesis.
- To create a platform for testing antiepileptic drug efficacy in such models.
Main Methods:
- Prenatal exposure of rats to methylazoxymethanol acetate (MAM) to induce neuronal migration disorders.
- Postnatal administration of AY-9944, a cholesterol biosynthesis inhibitor, to induce seizures.
- Characterization of seizure activity and histological examination of brain tissue.
Main Results:
- The combined MAM and AY-9944 treatment induced spontaneous, recurrent atypical absence seizures (6 Hz SWD).
- These seizures were refractory to common antiepileptic drugs like ethosuximide and sodium valproate.
- Histological analysis revealed cortical lamination abnormalities and hippocampal heterotopias.
Conclusions:
- The MAM-AY-treated rat is a reproducible model for refractory atypical absence seizures in pediatric brain dysgenesis.
- This model offers a valuable tool for understanding seizure pathogenesis and screening new epilepsy treatments.